Advertisement

Topics

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

2017-01-17 06:20:11 | BioPortfolio

Published on BioPortfolio: 2017-01-17T06:20:11-0500

Clinical Trials [3893 Associated Clinical Trials listed on BioPortfolio]

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and ...

Dose Escalation Study of OXi4503 as Single Agent and in Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS. Ph...

Lomustine and Intermediate Dose Cytarabine in Older Patients With AML

A multicenter randomized trial was performed comparing induction therapy (IC: Idarubicin and Cytarabine, 5+7) to ICL (the same drugs plus lomustine (CCNU), 200mg\m2 orally at day 1). Patie...

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failur...

Efficacy of FLAG Regimen for the Treatment of Patients With AML

The long-term efficacy of chemotherapy in patients with acute myeloid leukemia (AML) has been significantly improved in recent years. The combination of anthracycline plus cytarabine (Ara-...

PubMed Articles [6507 Associated PubMed Articles listed on BioPortfolio]

Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Neutropenia is a major risk factor for opportunistic infections in patients with acute myeloid leukemia (AML) who undergo chemotherapy. In the present study, we retrospectively compared the D-index, w...

Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.

The aim of this study is to determine whether the modified BuCy (semustine, cytarabine, busulfan, and cyclophosphamide, mBuCy) conditioning regimen can be safely used as an alternative to the SEAM (se...

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?

The combination of cytarabine and an anthracycline has been the standard of care for the induction of remission in acute myeloid leukemia (AML). The response to treatment and survival of adult patient...

Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.

CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leuke...

Medical and Biotech [MESH] Definitions

Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.

A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis.

Voluntary cooperation of the patient in following a prescribed regimen.

More From BioPortfolio on "Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial